IOVANCE BIOTHERAPEUTICS, INC.

IOVA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
389
SEC Filings

Business Summary

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company specializing in tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. Its two commercial products are Amtagvi (lifileucel), the first FDA-approved one-time individualized T cell therapy for previously treated advanced melanoma, and Proleukin (aldesleukin), an IL-2 product used in the Amtagvi treatment regimen. The company conducts centralized, scalable manufacturing and has ongoing registrational trials in frontline melanoma and non-small cell lung cancer.

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionIOVAdiscussed_in_filing Cybersecurity
topic_mentionIOVAdiscussed_in_filing Trusted Computing
topic_mentionIOVAdiscussed_in_filing Blockchain & Crypto
topic_mentionIOVAdiscussed_in_filing Regulation
topic_mentionIOVAdiscussed_in_filing Healthcare & Bio
topic_mentionIOVAdiscussed_in_filing AI Compute
topic_mentionIOVAdiscussed_in_filing Platform & Ecosystem
topic_mentionIOVAdiscussed_in_filing Sovereign & Government
topic_mentionIOVAdiscussed_in_filing Cybersecurity
topic_mentionIOVAdiscussed_in_filing Trusted Computing
topic_mentionIOVAdiscussed_in_filing Blockchain & Crypto
topic_mentionIOVAdiscussed_in_filing Regulation
topic_mentionIOVAdiscussed_in_filing Healthcare & Bio
topic_mentionIOVAdiscussed_in_filing AI Compute
topic_mentionIOVAdiscussed_in_filing Platform & Ecosystem
topic_mentionIOVAdiscussed_in_filing Sovereign & Government
topic_mentionIOVAdiscussed_in_filing Cybersecurity
topic_mentionIOVAdiscussed_in_filing Trusted Computing
topic_mentionIOVAdiscussed_in_filing Blockchain & Crypto
topic_mentionIOVAdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-242025-12-310001104659-26-018899EDGAR118K words
2025-02-272024-12-310001558370-25-001834EDGAR—
2024-02-282023-12-310001558370-24-002036EDGAR—
2023-02-282022-12-310001558370-23-002419EDGAR—
2022-02-242021-12-310001558370-22-001976EDGAR—
2021-02-252020-12-310001558370-21-001858EDGAR—
2020-02-252019-12-310001104659-20-024830EDGAR—
2019-02-282018-12-310001144204-19-010702EDGAR—
2018-03-122017-12-310001144204-18-014151EDGAR—
2017-03-092016-12-310001144204-17-013535EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001104659-25-107470EDGAR87K words
2025-08-072025-06-300001558370-25-010807EDGAR—
2025-05-082025-03-310001558370-25-007009EDGAR—
2024-11-072024-09-300001558370-24-014905EDGAR—
2024-08-082024-06-300001558370-24-011641EDGAR—
2024-05-092024-03-310001558370-24-007646EDGAR—
2023-11-072023-09-300001558370-23-018029EDGAR—
2023-08-082023-06-300001558370-23-013988EDGAR—
2023-05-102023-03-310001558370-23-009134EDGAR—
2022-11-032022-09-300001558370-22-016295EDGAR—
2022-08-042022-06-300001558370-22-012263EDGAR—
2022-05-052022-03-310001558370-22-007449EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-200001104659-26-032774EDGAR1K words
2026-02-240001104659-26-018837EDGAR—
2026-01-090001104659-26-002323EDGAR—
2025-11-060001104659-25-107426EDGAR—
2025-08-290001104659-25-085650EDGAR—
2025-08-220001104659-25-081953EDGAR—
2025-08-190001104659-25-080304EDGAR—
2025-08-070001104659-25-075175EDGAR—
2025-07-150001104659-25-067940EDGAR—
2025-07-030001104659-25-065781EDGAR—

389 total filings indexed. 357 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

advanced-melanoma non-small-cell-lung-cancer-(nsclc) undifferentiated-pleomorphic-sarcoma-(ups) dedifferentiated-liposarcoma-(ddlps) solid-tumor-oncology til-(tumor-infiltrating-lymphocyte)-cell-therapy-manufacturing centralized-scalable-proprietary-manufacturing-process lymphodepletion-treatment-regimen

Company Identity

CIK0001425205
TickerIOVA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: fc6707e3fc8c378c62499de08d06e2c1f82bf55defe95c9bc5775c521591bfdd
parent: 2c9216dd4db74a73c83480b506f516a75a564793ab6c9fda05ab753c1762dd4d
content hash: 0be8f13718af6e07cafa602936730cbfde83aad4804345b8b9dc91357b95539f
signed: 2026-04-13T04:45:43.866Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf